Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016, Article ID 7863867, 6 pages
http://dx.doi.org/10.1155/2016/7863867
Research Article

Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous Population

1University of Auckland, Waikato Clinical Campus, Private Bag 3200, Hamilton 3240, New Zealand
2Department of Endocrinology, Waikato Hospital, Private Bag 3200, Hamilton 3240, New Zealand

Received 3 February 2016; Accepted 22 May 2016

Academic Editor: Jack Wall

Copyright © 2016 Jade A. U. Tamatea et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Brandt, A. Green, L. Hegedüs, and T. H. Brix, “A critical review and meta-analysis of the association between overt hyperthyroidism and mortality,” European Journal of Endocrinology, vol. 165, no. 4, pp. 491–497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Carlé, I. B. Pedersen, N. Knudsen et al., “Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study,” European Journal of Endocrinology, vol. 164, no. 5, pp. 801–809, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. No Authors Listed, “Thyroid disease-more research needed,” The Lancet, vol. 379, no. 9821, p. 1076, 2012. View at Google Scholar
  4. S. Hertz and A. Roberts, “Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism,” JAMA, vol. 131, no. 2, pp. 81–86, 1946. View at Publisher · View at Google Scholar
  5. E. Chapman and R. Evans, “The treatment of hyperthyroidism with radioactive iodine,” The Journal of the American Medical Association, vol. 131, no. 2, pp. 86–91, 1946. View at Publisher · View at Google Scholar
  6. H. C. Ford, J. W. Delahunt, and C. M. Feek, “The management of Graves' disease in New Zealand: results of a national survey,” The New Zealand Medical Journal, vol. 104, no. 914, pp. 251–252, 1991. View at Google Scholar
  7. D. F. Schneider, P. E. Sonderman, M. F. Jones et al., “Failure of radioactive iodine in the treatment of hyperthyroidism,” Annals of Surgical Oncology, vol. 21, no. 13, pp. 4174–4180, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Lewis, T. Rea, B. Atkinson et al., “Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen,” Ulster Medical Journal, vol. 82, no. 2, pp. 85–88, 2013. View at Google Scholar · View at Scopus
  9. K. Boelaert, A. A. Syed, N. Manji et al., “Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism,” Clinical Endocrinology, vol. 70, no. 1, pp. 129–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Metso, P. Jaatinen, H. Huhtala, T. Luukkaala, H. Oksala, and J. Salmi, “Long-term follow-up study of radioiodine treatment of hyperthyroidism,” Clinical Endocrinology, vol. 61, no. 5, pp. 641–648, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Erem, N. Kandemir, A. Hacihasanoglu, H. Ö. Ersöz, K. Ukinc, and M. Kocak, “Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome,” Endocrine, vol. 25, no. 1, pp. 55–60, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Allahabadia, J. Daykin, M. C. Sheppard, S. C. L. Gough, and J. A. Franklyn, “Radioiodine treatment of hyperthyroidism—prognostic factors for outcome,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 8, pp. 3611–3617, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. J. J. Jacob, C. Stephen, T. V. Paul, N. Thomas, R. Oommen, and M. S. Seshadri, “No impact of dietary iodine restriction in short term development of hypothyroidism following fixed dose radioactive iodine therapy for graves disease,” Indian Journal of Endocrinology and Metabolism, vol. 19, no. 1, pp. 60–65, 2015. View at Publisher · View at Google Scholar
  14. J. Cepková, J. Horáček, J. Vižďa, and J. Doležal, “Radioiodine treatment of Graves' disease—dose/response analysis,” Acta Medica, vol. 57, no. 2, pp. 49–55, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Haryampudi, A. Hamide, D. Halanaik, J. P. Sahoo, and S. Kamalanthan, “Radioiodine therapy in patients with Graves' disease and the effects of prior carbimazole therapy,” Indian Journal of Endocrinology and Metabolism, vol. 18, no. 5, pp. 688–693, 2014. View at Google Scholar
  16. M. Liu, D. Jing, J. Hu, and S. Yin, “Predictive factors of outcomes in personalized radioactive iodine (131I) treatment for Graves' disease,” The American Journal of the Medical Sciences, vol. 348, no. 4, pp. 288–293, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. F. W. Gibb, N. N. Zammitt, G. J. Beckett, and M. W. J. Strachan, “Predictors of treatment failure, incipient hypothyroidism, and weight gain following radioiodine therapy for Graves' thyrotoxicosis,” Journal of Endocrinological Investigation, vol. 36, no. 9, pp. 764–769, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. F. de Jong, H. M. Verkooijen, G. D. Valk, P. M. J. Zelissen, and B. de Keizer, “High failure rates after 131I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover,” Clinical Nuclear Medicine, vol. 38, no. 6, pp. 401–406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Sztal-Mazer, V. Y. Nakatani, L. G. Bortolini, C. L. Boguszewski, H. Graf, and G. A. de Carvalho, “Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses,” Thyroid, vol. 22, no. 10, pp. 991–995, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Collier, S. Ghosh, M. Hair, I. Malik, and J. McGarvie, “Comparison of two fixed activities of radioiodine therapy (370 vs. 555 MBq) in patients with Graves' disease,” Hormones, vol. 8, no. 4, pp. 273–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. N. M. Gómez-Arnaiz, E. M. Andía, A. M. Gumà, R. M. Abós, J. M. Soler, and J. M. Gómez, “Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism,” Hormone and Metabolic Research, vol. 35, no. 8, pp. 492–497, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. E. K. Alexander and P. R. Larsen, “High dose 131I therapy for the treatment of hyperthyroidism caused by Graves' disease,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 3, pp. 1073–1077, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Allahabadia, J. Daykin, R. L. Holder, M. C. Sheppard, S. C. L. Gough, and J. A. Franklyn, “Age and gender predict the outcome of treatment for Graves' hyperthyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1038–1042, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. A. B. Watson, B. E. W. Brownlie, C. M. Frampton, J. G. Turner, and T. G. H. Rogers, “Outcome following standardized 185 MBq dose 131I therapy for Graves' disease,” Clinical Endocrinology, vol. 28, no. 5, pp. 487–496, 1988. View at Publisher · View at Google Scholar · View at Scopus
  25. Statistics New Zealand 2006 Census QuickStats about Māori. Statistics New Zealand website, 2006, http://www.stats.govt.nz.
  26. S. J. Bonnema and L. Hegedüs, “Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome,” Endocrine Reviews, vol. 33, no. 6, pp. 920–980, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Braga, N. Walpert, H. B. Burch, B. L. Solomon, and D. S. Cooper, “The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial,” Thyroid, vol. 12, no. 2, pp. 135–139, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. V. A. Andrade, J. L. Gross, and A. L. Maia, “The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 8, pp. 3488–3493, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. L. M. Prieto-Sanchez, G. E. Kiros, C. B. Hart, and V. Faugue, “Clinical presentation and response to therapy of Graves’ disease in a multi-ethnic endocrine clinic,” in Proceedings of the Endocrine Society's 95th Annual Meeting & Expo, Presentation Number MON-454, San Francisco, Calif, USA, 2013.
  30. A. M. Sawka, L. Thabane, L. Parlea et al., “Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis,” Thyroid, vol. 19, no. 5, pp. 451–457, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Metso, A. Auvinen, H. Huhtala, J. Salmi, H. Oksala, and P. Jaatinen, “Increased cancer incidence after radioiodine treatment for hyperthyroidism,” Cancer, vol. 109, no. 10, pp. 1972–1979, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Ryödi, S. Metso, P. Jaatinen et al., “Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 10, pp. 3710–3717, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Cormack, G. Purdie, and B. Robson, “Cancer,” in Hauora: Māori Standards of Health IV: A Study of the Years 2000–2005, B. Robson and R. Harris, Eds., chapter 6, pp. 103–119, Te Rōpū Rangahau Hauora a Eru Pōmare, Wellington, New Zealand, 2007. View at Google Scholar